Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer

Klepp, Olbjørn; Dahl, Olav; Flodgren, Per; Stierner, Ulrika; Olsson, Anders; Oldbring, Jörgen; Nilsson, Sten; Daehlin, L.; Törnblom, Magnus; Småland, R.; Starkhammar, Hans; Abramsson, Leif; Wist, Erik; Raabe, Nils; Edekling, Thomas; Cavallin‐Ståhl, Eva

doi:10.1016/s0959-8049(97)00041-5

Cited by 81 publications

(31 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[39][40][41][42][43][44][45][46][47][48] A total of 1768 patients were evaluated and with a median follow-up range of 19.5 to 76 months, 378 recurrences were reported (21.4%). Across the studies, 13 deaths from testicular cancer were reported, along with 7 other deaths.…”

Section: Surveillancementioning

confidence: 99%

“…The survival outcomes are summarized in Table 5. 13,[45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63] The presence of microscopic vascular or lymphatic invasion in the primary tumour is the most important factor predicting relapse and the presence or absence of this factor has been used to divide patients: those with high-risk disease (a third of the cases) who have about a 50% risk of relapse, and those with low-risk disease who have about a 15% to 20% risk of relapse. 45 …”

Section: E25mentioning

confidence: 99%

“…39,48,64 Across these studies, 344 patients were followed for a median time ranging from 21 to 40 months, and a total of 41 recurrences were found. There was 1 death from testicular cancer and 1 other death from unrelated causes.…”

Section: Retroperiteonal Lymph Node Dissectionmentioning

confidence: 99%

“…39,48,65,[71][72][73][74][75] Because the RCT compared adjuvant chemotherapy to RPLND, only the chemotherapy arm was included in the meta-analysis. Although the follow-up times of the included studies varied, all had sufficient follow-up that almost all recurrences that would occur among these patients were included.…”

Section: Adjuvant Chemotherapymentioning

confidence: 99%

See 3 more Smart Citations

Canadian consensus guidelines for the management of testicular germ cell cancer

Wood

Kollmannsberger

Jewett

et al. 2013

CUAJ

123

View full text Add to dashboard Cite

Section: Surveillancementioning

confidence: 99%

Section: E25mentioning

confidence: 99%

Section: Retroperiteonal Lymph Node Dissectionmentioning

confidence: 99%

Section: Adjuvant Chemotherapymentioning

confidence: 99%

See 2 more Smart Citations

Canadian consensus guidelines for the management of testicular germ cell cancer

Wood

Kollmannsberger

Jewett

et al. 2013

CUAJ

123

View full text Add to dashboard Cite

“…Treatment was given according to the Swedish Norwegian Testicular Cancer Group (Swenoteca) protocols (16,17).…”

Section: Cancer Treatmentmentioning

confidence: 99%

Risk factors for post-treatment hypogonadism in testicular cancer patients.

Eberhard

Ståhl

Cwikiel

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Objectives: Testicular germ-cell cancer (TGCC) patients are at risk of developing hypogonadism but no risk factors have yet been defined. Methods: Blood was collected from 143 TGCC patients (after orchidectomy, prior to further therapy (T0) and 6, 12, 24, 36 and 60 months (T6, T12, T24, T36 and T60) after therapy). Biological hypogonadism (BH) was defined as: serum testosterone below 10 nmol/l and/or LH O10 IU/l; odds ratios (ORs) for BH with BH at T0, age, stage of disease, testicular characteristics, and androgen receptor polymorphism as predictors were calculated as well as the OR for developing BH post-treatment (one to two cycles of adjuvant chemotherapy (ACT) versus three to four cycles of higher dose chemotherapy (HCT) versus adjuvant radiotherapy (RT)). Results: HCT increased the OR for BH at T6 (OR 22, 95% confidence interval (CI) 4.4-118) and T12 (OR 5.8, 95% CI 1.5-22). RT increased the OR at T6 (OR 10, 95% CI 2.1-47) and at T12 (OR 3.9, 95% CI 1.1-14). Microlithiasis predicted BH at T0 (OR 11, 95% CI 1.2-112), T12 (OR 3.9, 95% CI 1.1-13), T24 (OR 3.0, 95% CI 1.0-8.8), T36 (OR 5.4, 95% CI 1.7-17) and T60 (OR 4.4, 95% CI 1.2-16). BH at T0 was a risk for BH at T6 (OR 53,, T12 (OR 125, 95% CI 37-430), T24 (OR 88, 95% CI 26-300) and T36 (OR 121, 95% CI 32-460). Conclusions: It is clinically relevant that BH at T0 and testicular microlithiasis were predictive factors for post-treatment BH. HCT and RT gave temporary BH.

show abstract